Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer Founded in 2013, headquartered in New York City, United States. The company has raised $20M at the Series A stage backed by investors including Bruker, XLerateHealth. Operating in Life Sciences > Genomics, Life Sciences > Oncology.
← All startups
AcuamarkDx
Series AProvider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Gastrointestinal Cancer > Colorectal Cancer,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA and RNA
Institutional investors
BrukerXLerateHealthClaudio Del Vecchio
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.